Mirati Therapeutics, Inc. Common Stock
MRTX
MRTX was delisted on the 22nd of January, 2024.
49 hedge funds and large institutions have $204M invested in Mirati Therapeutics, Inc. Common Stock in 2017 Q3 according to their latest regulatory filings, with 14 funds opening new positions, 16 increasing their positions, 11 reducing their positions, and 15 closing their positions.
273% more capital invested
Capital invested by funds: $54.8M → $204M (+$149M)
182% more call options, than puts
Call options by funds: $2.47M | Put options by funds: $874K
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
45% more repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 11
7% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 15
4% less funds holding
Funds holding: 51 → 49 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACA
Avoro Capital Advisors
New York
|
+$8.3M |
| 2 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$5.79M |
| 3 |
D.E. Shaw & Co
New York
|
+$2.87M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.78M |
| 5 |
Millennium Management
New York
|
+$1.32M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HIM
Hillhouse Investment Management
Grand Cayman,
Cayman Islands
|
-$2.65M |
| 2 |
SM
Sabby Management
Miami Beach,
Florida
|
-$921K |
| 3 |
Alyeska Investment Group
Chicago,
Illinois
|
-$893K |
| 4 |
ECM
Element Capital Management
New York
|
-$520K |
| 5 |
HP
Hikari Power
Tokyo,
Japan
|
-$365K |
MRTX Hedge Fund Activity: Q3 2017 in Review
49 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Mirati Therapeutics, Inc. Common Stock (MRTX) for Q3 2017, worth a combined $204M — up 273% from $54.8M a quarter earlier.
Sellers outnumbered buyers: 15 funds closed out of MRTX and 14 opened new positions — a net loss of 1 holder — while 11 trimmed existing stakes and 16 added.
The largest buyer was Avoro Capital Advisors, adding an estimated $8.3M. The largest seller was Hillhouse Investment Management, exiting entirely with an estimated $2.65M sold.
- 49 institutional investors held Mirati Therapeutics, Inc. Common Stock (MRTX) as of Q3 2017, down from 51 in Q2 2017.
- Funds reported $204M of Mirati Therapeutics, Inc. Common Stock stock for Q3 2017, up 273% quarter-over-quarter.
- 14 funds opened new Mirati Therapeutics, Inc. Common Stock positions in Q3 2017 and 15 closed out, a net change of -1 holder.
- The largest Mirati Therapeutics, Inc. Common Stock buyer in Q3 2017 was Avoro Capital Advisors, an estimated $8.3M added.
- The largest Mirati Therapeutics, Inc. Common Stock seller in Q3 2017 was Hillhouse Investment Management, an estimated $2.65M sold.
Based on aggregated 13F filings for Q3 2017.